Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Drug Delivery: Overview01:16

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nocturia in postmenopausal women.

Menopause (New York, N.Y.)·2026
Same author

A Contemporary View of Menopausal Hormone Therapy: Correction.

Obstetrics and gynecology·2026
Same author

Quantification of "Mercy Sex" in Heterosexual Women.

Journal of sex & marital therapy·2026
Same author

Report of the FDA's expert panel on hormone therapy.

Menopause (New York, N.Y.)·2026
Same author

Tailoring transdermal estradiol dose to maximize benefits and minimize risks.

Menopause (New York, N.Y.)·2026
Same author

Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

AJOG global reports·2026
Same journal

Intrinsic capacity and the trajectory of ischemic heart disease and its complications: the mediating role of insulin resistance indices.

Maturitas·2026
Same journal

Mobility limitation trajectories and longitudinal changes in delayed recall in midlife and later life: A multicohort study.

Maturitas·2026
Same journal

Digital twins in menopause: a roadmap for integrating endocrine dynamics, multisystem physiology, and precision medicine.

Maturitas·2026
Same journal

Testosterone therapy in women: Keeping pace with the evidence.

Maturitas·2026
Same journal

Diagnosis and management of androgen excess presenting after menopause.

Maturitas·2026
Same journal

Domain-specific severity of menopausal symptoms and emotional eating in midlife women.

Maturitas·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Nanoparticle delivery for transdermal HRT.

Pilar Valenzuela1, James A Simon

  • 1Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, School of Medicine, Santiago, Chile. pvalenzu@uc.cl

Maturitas
|February 14, 2012
PubMed
Summary
This summary is machine-generated.

Nanoparticle drug delivery offers advantages for transdermal hormone therapy. Micellar nanoparticle estradiol emulsion (MNPEE) provides an effective, safe option for menopausal symptom relief with minimal skin irritation.

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Experiment Videos

Last Updated: May 25, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Area of Science:

  • Nanomedicine and drug delivery systems.
  • Pharmacology and therapeutic applications.
  • Dermatology and skin interactions.

Background:

  • Transdermal drug delivery bypasses first-pass metabolism, offering advantages over oral administration.
  • Traditional transdermal estrogen therapy can cause skin irritation and adverse effects, leading to discontinuation.
  • Nanoparticles offer unique properties for enhanced substance transport across the skin.

Purpose of the Study:

  • To review nanoparticle delivery systems for transdermal administration.
  • To discuss the application of nanomedicine in transdermal hormone therapy.
  • To evaluate Micellar Nanoparticle Estradiol Emulsion (MNPEE) as a novel transdermal delivery system.

Main Methods:

  • Review of existing literature on nanoparticle transdermal delivery.
  • Evaluation of clinical trial data for MNPEE efficacy and safety.
  • Analysis of studies on estradiol transference in partner studies.

Main Results:

  • MNPEE demonstrates low plasma estradiol fluctuations and infrequent skin adverse effects.
  • Efficacy in managing moderate to severe vasomotor symptoms was confirmed in a randomized trial.
  • Estradiol transference to male partners was minimal and within physiological ranges.

Conclusions:

  • MNPEE is a safe and effective transdermal estrogen therapy for postmenopausal vasomotor symptoms.
  • It represents a validated commercial application of nanoparticle technology for hormone replacement.
  • MNPEE offers a well-tolerated alternative to conventional transdermal systems, avoiding permeation enhancers.